ELOVL2 Gene Expression Linked with Age-Related Eye Diseases

Located in Tucson, Arizona, Retina Associates serves the needs of patients requiring a wide range of eye care services. Led by Dr. Cameron Javid, the experienced Retina Associates team has an extensive understanding of the latest trends in medical technology and research regarding vision and eye health.

One recent University of California, San Diego mice model study brought focus to the Elongation of very long chain fatty acids protein 2 gene (ELOVL2) gene and its role in the eye’s aging process. The ELOVL2 gene has a critical role in producing long-chain omega-6 and omega-3 polyunsaturated fatty acids, which are essential to inflammation response and energy production, as well as ensuring cell membrane integrity.

The new study shows that ELOVL2 gene expression also regulates aging in the retina, and finds a molecular-level linkage between fatty acids that it regulates, such as DHA, and visual functions. DHA is known for its beneficial effects in the eye, including protection from oxidative, or bright-light, stress, and when present in the photoreceptors promotion of a healthy retina. It is also linked to improvements in conditions such as dry eyes, diabetic eye disease, and age-related macular (AMD) degeneration.

The research suggests that ELOVL2 is related to a number of conditions that emerge as people grow older, and that encouraging its expression may be a key to tackling age-related eye diseases.

The Symptoms and Effects of Macula Degeneration

Introducing the American College of Surgeons GVS Program

Located in Tucson, Arizona, Retina Associates provides advanced care for diseases impacting the retina, macula, and vitreous. The office is staffed by physicians certified by the American Board of Ophthalmology, including Cameron Javid MD FACS, Retina Associates engages with a number of organizations, including the American College of Surgeons.

The American College of Surgeons (ACS) has recently introduced the ACS Geriatric Surgery Verification (GSV) Program. Through this quality-improvement initiative, 30 unique surgical standards have been developed, with a mission of comprehensively elevating surgical practices and prognoses for the nation’s expanding senior population. Hospitals that adopt the ACS GSV Program will enjoy a streamlined groundwork for optimized support and outcomes for older patients.

The ACS Coalition for Quality in Geriatric Surgery Project established the program in partnership with the John A. Hartford Foundation, representing the collective input of numerous regulatory groups, health care leaders, patients, advocacy organizations, and more. Standards developed through the program touch on various areas of medical care, from tips for improved patient communications to revised screening schedules for geriatric vulnerabilities. More information about the GSV Program can be found online at http://www.facs.org.

Understanding Uveal Melanoma and Its Treatment Options

 

Retina Associates
Image: retinatucson.com

Retina Associates is an ophthalmology practice located in Tucson, Arizona, where Dr. Cameron Javid and his fellow physicians provide surgical treatment for a wide range of eye conditions. The team at Retina Associates focuses on retinal tears and detachment, as well as diabetes-related eye disorders and tumors inside the eye.

Uveal melanoma is regarded as one of the deadliest eye diseases among adults. In the United States, about 2,000 individuals per year are diagnosed with it, Unfortunately, there hasn’t been enough research done to identify its exact cause or common risk factors. Overexposure to sunlight was once thought to be a major factor, but that has since been proven inaccurate. Smoking is considered a risk factor. Yet, there are proven obscure risk factors such as potential associations dysplastic nevus syndrome, and melanosis oculi. People with fair skin and light colored eyes are at risk.

The disease can occur within three areas of the eye: the iris, the ciliary body, and the choroid – and half of those patients will develop the fatal metastatic form of the disease within 10 to 15 years after diagnosis. The primary form of treatment is radiation therapy, which is given to roughly 80 percent of patients and is available in two forms: proton beam radiotherapy and plaque brachytherapy, the latter of which is the most common.

Those with larger tumors might require enucleation, which involves removing the eye and optic nerve while retaining the nearby orbital adnexal tissue and attaching a spherical orbital implant. A custom-made prosthesis replaces the implant 6-8 weeks after surgery.